Incorporating muscle assessments from whole-body MRIs (WB-MRIs) into the diagnostic process for amyotrophic lateral sclerosis (ALS) may help identify the condition with a greater degree of certainty, according to a study from France. ALS causes damage to specialized nerve cells called motor neurons. Some criteria for diagnosing ALS…
News
Oral amyotrophic lateral sclerosis (ALS) treatment PrimeC significantly reduced levels of TDP-43, a protein that abnormally accumulates in nearly all ALS cases, in a Phase 2b clinical trial. The PARADIGM study met its main efficacy goal of lowering TDP-43 levels in nerve cells relative to a placebo after six months.
Former NFL running back Chris Johnson, whose historic 2,000 rushing yards in a season earned him the nickname CJ2K, has revealed that he is living with amyotrophic lateral sclerosis (ALS), saying he hopes sharing his story will encourage earlier diagnoses, inspire more research, and give hope to others facing…
Trace Neuroscience has launched its clinical development program for TRCN-1023, an experimental treatment for amyotrophic lateral sclerosis (ALS) that is designed to restore the function of UNC13A, a protein involved in nerve-muscle communication. The global clinical program includes FUNCTION ALS, a company-sponsored Phase 1/2 clinical trial authorized…
The lowest tested dose of Amylyx Pharmaceuticals‘ treatment candidate AMX0114 was found to be safe and well tolerated among people with amyotrophic lateral sclerosis (ALS) in an ongoing Phase 1 clinical trial. Biomarkers of nerve damage due to ALS remained relatively stable from the study’s start — a result…
The first patient has been dosed in a Phase 1/2 clinical trial evaluating Leal Therapeutics‘ LTX-002, an antisense oligonucleotide designed to target abnormalities in fat metabolism that may contribute to amyotrophic lateral sclerosis (ALS). The NeurALS trial (NCT07660614) is now recruiting an estimated 56 adults with ALS at…
Nura Bio has raised $73.8 million to support two experimental therapies designed to protect nerve cells from damage, including one that is already being tested in people with amyotrophic lateral sclerosis (ALS). Proceeds from the Series B financing round, usually the second major funding round for…
Treatment burden — the workload associated with managing a disease, including taking medications, attending medical appointments, and carrying out self-care tasks — was reported by nearly 70% of patients with amyotrophic lateral sclerosis (ALS), according to a study in Italy. Among patients reporting any burden, more than half were…
Lower blood levels of adiponectin, a signaling molecule produced by fat tissue, and the anti-inflammatory molecule interleukin (IL)-10 are associated with faster disease progression and shorter survival in people with amyotrophic lateral sclerosis (ALS), a study in China found. The findings also showed that established prognostic measures, such as…
Projenx‘s prosetin was found to be safe and well tolerated at doses that engaged its therapeutic target in people with amyotrophic lateral sclerosis (ALS), supporting its continued development as a potential disease-modifying therapy. These interim data from the fully enrolled PRO-101 Phase 1 clinical trial (NCT05279755), including…
Recent Posts
- How new gene therapies are transforming genetic testing for ALS
- A trip to the ER makes me thankful I still have my parenting partner
- PBS documentary on runner with ALS explores identity, caregiving
- A new wheelchair means making adjustments mentally and physically
- Real-world study sheds new light on safety of approved ALS drug